vs
Cellectis S.A.（CLLS）与Bio-Techne（TECH）财务数据对比。点击上方公司名可切换其他公司
Bio-Techne的季度营收约是Cellectis S.A.的31.1倍（$295.9M vs $9.5M）。Bio-Techne净利率更高（12.8% vs -265.9%，领先278.7%）。Cellectis S.A.同比增速更快（375.0% vs -6.4%）
Cellectis S.A.是一家法国生物制药公司，专注于开发用于癌症免疫治疗的基因编辑嵌合抗原受体T细胞技术，目前在巴黎、纽约以及北卡罗来纳州罗利均设有办公机构，在肿瘤免疫基因编辑疗法领域拥有多年研发积累。
Bio-Techne是美国头部生命科学企业，面向科研、诊断及生物工艺市场需求，研发、生产并销售生命科学试剂、仪器及配套服务，产品及解决方案广泛应用于基础研究、体外诊断、生物医药研发生产等场景，可为相关领域从业者提供可靠的专业工具支持。
CLLS vs TECH — 直观对比
营收规模更大
TECH
是对方的31.1倍
$9.5M
营收增速更快
CLLS
高出381.4%
-6.4%
净利率更高
TECH
高出278.7%
-265.9%
损益表 — Q2 2024 vs Q2 2026
| 指标 | | |
|---|---|---|
| 营收 | $9.5M | $295.9M |
| 净利润 | $-25.3M | $38.0M |
| 毛利率 | — | 64.6% |
| 营业利润率 | -181.1% | 18.4% |
| 净利率 | -265.9% | 12.8% |
| 营收同比 | 375.0% | -6.4% |
| 净利润同比 | -51.9% | 68.3% |
| 每股收益（稀释后） | $-0.28 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLLSTECH
| Q4 25 | — | $295.9M | ||
| Q2 25 | — | $317.0M | ||
| Q1 25 | — | $316.2M | ||
| Q4 24 | — | $297.0M | ||
| Q3 24 | — | $289.5M | ||
| Q2 24 | $9.5M | $306.1M | ||
| Q1 24 | — | $303.4M | ||
| Q4 23 | — | $272.6M |
净利润CLLSTECH
| Q4 25 | — | $38.0M | ||
| Q2 25 | — | $-17.7M | ||
| Q1 25 | — | $22.6M | ||
| Q4 24 | — | $34.9M | ||
| Q3 24 | — | $33.6M | ||
| Q2 24 | $-25.3M | $40.6M | ||
| Q1 24 | — | $49.1M | ||
| Q4 23 | — | $27.5M |
毛利率CLLSTECH
| Q4 25 | — | 64.6% | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% | ||
| Q1 24 | — | 67.4% | ||
| Q4 23 | — | 64.8% |
营业利润率CLLSTECH
| Q4 25 | — | 18.4% | ||
| Q2 25 | — | -7.5% | ||
| Q1 25 | — | 12.2% | ||
| Q4 24 | — | 16.0% | ||
| Q3 24 | — | 13.8% | ||
| Q2 24 | -181.1% | 15.0% | ||
| Q1 24 | — | 22.1% | ||
| Q4 23 | — | 13.9% |
净利率CLLSTECH
| Q4 25 | — | 12.8% | ||
| Q2 25 | — | -5.6% | ||
| Q1 25 | — | 7.1% | ||
| Q4 24 | — | 11.7% | ||
| Q3 24 | — | 11.6% | ||
| Q2 24 | -265.9% | 13.3% | ||
| Q1 24 | — | 16.2% | ||
| Q4 23 | — | 10.1% |
每股收益（稀释后）CLLSTECH
| Q4 25 | — | $0.24 | ||
| Q2 25 | — | $-0.11 | ||
| Q1 25 | — | $0.14 | ||
| Q4 24 | — | $0.22 | ||
| Q3 24 | — | $0.21 | ||
| Q2 24 | $-0.28 | $0.26 | ||
| Q1 24 | — | $0.31 | ||
| Q4 23 | — | $0.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $149.0M | $172.9M |
| 总债务越低越好 | — | $260.0M |
| 股东权益账面价值 | $148.6M | $2.0B |
| 总资产 | $407.1M | $2.5B |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资CLLSTECH
| Q4 25 | — | $172.9M | ||
| Q2 25 | — | $162.2M | ||
| Q1 25 | — | $140.7M | ||
| Q4 24 | — | $177.5M | ||
| Q3 24 | — | $187.5M | ||
| Q2 24 | $149.0M | $152.9M | ||
| Q1 24 | — | $145.3M | ||
| Q4 23 | — | $135.7M |
总债务CLLSTECH
| Q4 25 | — | $260.0M | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | — | $389.0M | ||
| Q4 23 | — | $447.0M |
股东权益CLLSTECH
| Q4 25 | — | $2.0B | ||
| Q2 25 | — | $1.9B | ||
| Q1 25 | — | $2.0B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | — | $2.1B | ||
| Q2 24 | $148.6M | $2.1B | ||
| Q1 24 | — | $2.0B | ||
| Q4 23 | — | $2.0B |
总资产CLLSTECH
| Q4 25 | — | $2.5B | ||
| Q2 25 | — | $2.6B | ||
| Q1 25 | — | $2.6B | ||
| Q4 24 | — | $2.7B | ||
| Q3 24 | — | $2.7B | ||
| Q2 24 | $407.1M | $2.7B | ||
| Q1 24 | — | $2.7B | ||
| Q4 23 | — | $2.7B |
负债/权益比CLLSTECH
| Q4 25 | — | 0.13× | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.19× | ||
| Q4 23 | — | 0.23× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.9M | — |
| 自由现金流经营现金流 - 资本支出 | $27.6M | — |
| 自由现金流率自由现金流/营收 | 290.5% | — |
| 资本支出强度资本支出/营收 | 13.2% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CLLSTECH
| Q4 25 | — | — | ||
| Q2 25 | — | $98.2M | ||
| Q1 25 | — | $41.1M | ||
| Q4 24 | — | $84.3M | ||
| Q3 24 | — | $63.9M | ||
| Q2 24 | $28.9M | $75.5M | ||
| Q1 24 | — | $81.0M | ||
| Q4 23 | — | $83.1M |
自由现金流CLLSTECH
| Q4 25 | — | — | ||
| Q2 25 | — | $93.3M | ||
| Q1 25 | — | $31.0M | ||
| Q4 24 | — | $77.5M | ||
| Q3 24 | — | $54.7M | ||
| Q2 24 | $27.6M | $57.5M | ||
| Q1 24 | — | $64.5M | ||
| Q4 23 | — | $68.3M |
自由现金流率CLLSTECH
| Q4 25 | — | — | ||
| Q2 25 | — | 29.4% | ||
| Q1 25 | — | 9.8% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 18.9% | ||
| Q2 24 | 290.5% | 18.8% | ||
| Q1 24 | — | 21.3% | ||
| Q4 23 | — | 25.0% |
资本支出强度CLLSTECH
| Q4 25 | — | — | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 3.2% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | 13.2% | 5.9% | ||
| Q1 24 | — | 5.4% | ||
| Q4 23 | — | 5.5% |
现金转化率CLLSTECH
| Q4 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | — | 2.42× | ||
| Q3 24 | — | 1.90× | ||
| Q2 24 | — | 1.86× | ||
| Q1 24 | — | 1.65× | ||
| Q4 23 | — | 3.03× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLLS
暂无分部数据
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
